insights_auto
Kāpēc uzņēmuma EVT akciju cena ir samazinājusies 8,76%?
Atklājiet vairāk iespējuchevron_right
EVT:FRA
Evotec SE
2,83 €
arrow_downward
-8,76%(-0,27) 1 d.
7. okt., 22:00:00 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: EVT…
Atvērt
2,96 €
Augsta
2,96 €
Zema
2,83 €
Tirgus kapitalizācija
479,99 milj.
Vid. apjoms
4,58 tūkst.
Apjoms
1,90 tūkst.
Augstākā 52 ned.
7,49 €
Zemākā 52 ned.
2,73 €
Peļņa uz vienu akciju
-1,11 €
Apgrozībā esošās akcijas
148,72 milj.
Darbinieku skaits
4 tūkst.
Atvērt
2,96 €
Augsta
2,96 €
Zema
2,83 €
Tirgus kapitalizācija
479,99 milj.
Vid. apjoms
4,58 tūkst.
Apjoms
1,90 tūkst.
Augstākā 52 ned.
7,49 €
Zemākā 52 ned.
2,73 €
Peļņa uz vienu akciju
-1,11 €
Apgrozībā esošās akcijas
148,72 milj.
Darbinieku skaits
4 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
AD HOC NEWS
·
pirms 7 stundām
Evotec loses research chief. Evotec stock falls 2.03 percent
AD HOC NEWS
·
pirms 1 dienas
Evotec loses research chief and Evotec stock gains 2.36 percent
AD HOC NEWS
·
pirms 2 dienām
Evotec loses research chief. Evotec stock gains 2.05 percent
AD HOC NEWS
·
pirms 2 dienām
Evotec stock reports weaker 2026 guidance ahead of results
Profils
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Par “Evotec SE”
Ģenerāldirektors-
Darbinieki4,46 tūkst.
Dibināšanas datums1993
Galvenais birojs-
Sektors-
Tīmekļa vietneevotec.com